Hunger Neurons Help Sustain Weight Loss From GLP-1 Drugs

For decades, obesity medications produced only modest weight loss, but GLP-1 therapies like Ozempic have changed that in recent years, enabling sustained weight loss of 10 to 15% or more. Despite that success, scientists have not fully understood how these drugs work in the brain. A new study from Yale researchers has identified an unexpected mechanism that challenges a long-held assumption about the brain’s hunger circuitry: that agouti-related peptide (AgRP) neurons, known as drivers of hunger, function solely to oppose weight loss. Instead, the study shows that GLP-1 therapies recruit these neurons to help sustain fat loss. The findings appear in Proceedings of the National Academy of Sciences.

Semaglutide, the active ingredient in Ozempic, has become one of the most effective obesity medications ever developed, yet why it works so well has remained unclear. Earlier generations of weight-loss drugs suppressed appetite nearly as effectively as semaglutide, but none achieved the same degree of sustained weight loss, suggesting semaglutide does something beyond reducing appetite. One prevailing view held that GLP-1 drugs promote weight loss by reducing the activity of hunger-driving neurons, but the role of AgRP neurons during chronic GLP-1 treatment had never been directly tested in a living organism.

To investigate, the Yale team combined several approaches in a mouse model, tracking body weight, food intake, metabolism, and energy expenditure during semaglutide treatment. They also used genetic methods to selectively remove or silence AgRP neurons to test whether those neurons were necessary for the drug’s effects. In mice genetically modified to lack AgRP neurons, GLP-1 drugs could no longer sustain weight loss. Further experiments using electron microscopy, molecular biology, and electrophysiology showed that semaglutide activates these neurons rather than suppressing them.

The researchers say the findings suggest the brain adapts to the calorie deficit created by GLP-1 treatment by increasing AgRP neuron activity, which also coordinates fat loss, revealing a previously unrecognized layer of complexity in how these therapies work. Because the study was conducted in mice, more research is needed before the findings can be translated to humans, but understanding exactly how these medications act in the brain marks an important step toward developing future obesity treatments. 

“This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs,” said Mateus d’Ávila, the study’s first author. He added: “By identifying a previously unrecognized neural mechanism involved in sustaining weight loss, our work provides new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects.”